Form 4: Sangamo Officer Sells Shares for Tax Withholding

Sangamo Therapeutics' Principal Accounting Officer, Nikunj Jain, disposed of 6,708 shares of common stock to cover mandatory tax withholdings related to RSU vesting.

Summary

• Nikunj Jain, Principal Accounting Officer of Sangamo Therapeutics, Inc. (SGMO), reported a transaction on October 22, 2025.
• The transaction involved the disposition of 6,708 shares of common stock at a price of $0.66 per share.
• This disposition was solely for mandatory tax withholding purposes related to the vesting of Restricted Stock Units (RSUs) under the Issuer's Amended and Restated 2018 Equity Incentive Plan.
• The shares were surrendered to the Issuer and do not represent a discretionary trade by the Reporting Person in the open market.
• Following this transaction, Nikunj Jain beneficially owns 246,295 shares of common stock.
• The beneficially owned shares include 12,042 shares from the October 22, 2025 vesting installment of a January 22, 2024 RSU grant, plus remaining unvested portions from this and other RSU grants from February 24, 2023, and February 25, 2025.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary event for tax purposes related to RSU vesting, indicating neither significant positive nor negative sentiment for the company's operational performance.

Positives

• Vesting of Restricted Stock Units (RSUs) indicates the achievement of employment milestones or performance targets for the reporting person.
• The reporting person continues to hold a significant number of shares (246,295) and unvested RSUs, aligning their interests with shareholders.

Negatives

• The disposition of shares, even for tax purposes, reduces the reporting person's direct shareholding.
• The stock price used for the transaction was $0.66 per share, which might be considered low depending on historical performance.

Risks

• Future vesting of the remaining 246,295 shares is contingent upon the Reporting Person's 'Continuous Service' as defined in the 2018 Equity Incentive Plan.

Future Outlook

Remaining 18,750 shares from the January 22, 2024 RSU grant will vest in successive equal quarterly installments through January 22, 2026. Additionally, 3,235 shares from the February 24, 2023 RSU grant will vest in successive equal quarterly installments through February 24, 2026. Furthermore, 49,726 shares from the February 25, 2025 RSU grant will vest as to one-quarter on February 25, 2026, with the remainder vesting in 8 successive equal quarterly installments thereafter. All future vesting is subject to the Reporting Person's Continuous Service.

Industry Context

Routine insider transactions, such as dispositions for tax withholding upon RSU vesting, are common across publicly traded companies, particularly in the biotechnology sector where equity compensation is a significant component of executive pay. This filing reflects standard compensation practices rather than a unique industry event.

Comparison to Industry Standards

• The mechanism of surrendering shares for tax withholding upon RSU vesting is a standard practice for equity compensation plans across various industries, including biotechnology.
• This aligns with typical corporate governance and compensation structures for executives in U.S. public companies.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax-related transaction, not a discretionary sale. It reflects standard executive compensation practices.
• Employees: Reinforces the company's equity compensation structure for executives, potentially signaling stability in compensation practices.

Next Steps

• Successive equal quarterly installments of 18,750 shares from the January 22, 2024 RSU grant through January 22, 2026.
• Successive equal quarterly installments of 3,235 shares from the February 24, 2023 RSU grant through February 24, 2026.
• One-quarter (1/4) of 49,726 shares from the February 25, 2025 RSU grant will vest on February 25, 2026, with the remainder vesting in 8 successive equal quarterly installments thereafter.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by a company officer for mandatory tax withholding related to RSU vesting. Such transactions are common and do not typically reflect a change in the officer's confidence in the company or its future prospects. The filing does not contain new operational or financial information that would warrant a change in investment thesis, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Sangamo Therapeutics, SGMO, Form 4, insider transaction, RSU, restricted stock unit, tax withholding, beneficial ownership, Nikunj Jain, Principal Accounting Officer